Aspen Neuroscience's Parkinson's treatment, ANPD001, demonstrates safety and feasibility in non-human primates, supporting its Phase 1/2a clinical trial.
Aspen Neuroscience's ANPD001, an autologous dopaminergic neuronal cell replacement, is being investigated in a Parkinson's disease clinical trial as a potential treatment. A study published in the Journal of Neurosurgery demonstrated the safety and feasibility of ANPD001's cell transplantation approach in non-human primates. The research was conducted by the Wisconsin National Primate Research Center at the University of Wisconsin, Madison, and supports Aspen's current Phase 1/2a clinical trial, ASPIRO, for moderate to severe Parkinson's patients.
July 29, 2024
12 Articles